U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H20N6O3
Molecular Weight 440.454
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANDESARTAN

SMILES

CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(O)=O

InChI

InChIKey=HTQMVQVXFRQIKW-UHFFFAOYSA-N
InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.japsonline.com/admin/php/uploads/290_pdf.pdf

Candesartan is classified as an angiotensin II receptor type 1 antagonist. Candesartan is an orally active lipophilic drug and possesses rapid oral absorption. It causes a reduction in blood pressure and is used in the treatment of hypertension. It is also used in the treatment of congestive heart failure and given as prophylaxis to reduce the severity and duration of migraine. Candesartan cilexetil, a prodrug of Candesartan, is available in the market under the trade names Atacand, Amias. Candesartan cilexetil is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS (renin–angiotensin–aldosterone system). RAAS is a homeostatic mechanism for regulating hemodynamics, water, and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering the cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2.

CNS Activity

Curator's Comment: Candesartan crosses the blood-brain barrier poorly.

Originator

Curator's Comment: TCV-116 # Takeda, Osaka, Japan

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ATACAND

Approved Use

Candesartan Cilexetil Tablets are an angiotensin II receptor blocker (ARB) indicated for: •Treatment of hypertension in adults and children 1 to < 17 years of age (1.1). •Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to < 17 years of age. It may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Candesartan cilexetil tablets is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see CLINICAL STUDIES (14.2)

Launch Date

1998
Primary
ATACAND

Approved Use

Candesartan Cilexetil Tablets are an angiotensin II receptor blocker (ARB) indicated for: •Treatment of hypertension in adults and children 1 to < 17 years of age (1.1). •Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to < 17 years of age. It may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Candesartan cilexetil tablets is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see CLINICAL STUDIES (14.2)

Launch Date

1998
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
92 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
61 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
79 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
55 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1152 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
509 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1359 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
485 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.7 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.1 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.7 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
unknown, unknown
CANDESARTAN CILEXETIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Co-administed with::
amlodipine(10 mg/day)
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hepatitis...
AEs leading to
discontinuation/dose reduction:
Hepatitis (acute, 1 patient)
Sources:
32 mg 1 times / day steady, oral
Highest studied dose
Dose: 32 mg, 1 times / day
Route: oral
Route: steady
Dose: 32 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 6
Health Status: unhealthy
Condition: Type 2 Diabetes
Age Group: 59 years
Population Size: 6
Sources:
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Disc. AE: Hypotension, Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hypotension (4.1%)
Hyperkalemia (2.4%)
Sources:
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy
Other AEs: Disorder fetal...
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache (0.6%)
Dizziness (0.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatitis acute, 1 patient
Disc. AE
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Co-administed with::
amlodipine(10 mg/day)
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: F
Population Size: 1
Sources:
Hyperkalemia 2.4%
Disc. AE
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Hypotension 4.1%
Disc. AE
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Disorder fetal
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy
Dizziness 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
Headache 0.6%
Disc. AE
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
PubMed

PubMed

TitleDatePubMed
The mechanism of action of angiotensin II is dependent on direct activation of vascular smooth muscle carbonic anhydrase I.
2000
Angiotensin II AT(1) receptor antagonists and platelet activation.
2001
Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
2001 Apr
Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes.
2001 Apr
Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation.
2001 Apr
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
2001 Apr
Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats.
2001 Apr
Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization.
2001 Apr
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
2001 Aug
Role of nNOS in regulation of renal function in angiotensin II-induced hypertension.
2001 Aug
Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.
2001 Feb
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
2001 Feb
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
2001 Jan-Feb
Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts.
2001 Jul
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
2001 Jul
Activation of angiotensin II subtype 2 receptor induces catecholamine release in an extracellular Ca(2+)-dependent manner through a decrease of cyclic guanosine 3',5'-monophosphate production in cultured porcine adrenal medullary chromaffin Cells.
2001 Jul
Possible roles of cardiac chymase after myocardial infarction in hamster hearts.
2001 Jun
Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation.
2001 Jun
Endogenous angiotensin II in the NTS contributes to sympathetic activation in rats with aortocaval shunt.
2001 Jun
Lithium intoxication after administration of AT1 blockers.
2001 Mar
Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.
2001 Mar
Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.
2001 May
Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats.
2001 May
[Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
2001 May 11
Tight binding of the angiotensin AT(1) receptor antagonist.
2001 May 15
Angiotensin-II-receptor inhibitors in pregnancy.
2001 May 19
Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
2001 Nov
Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis.
2001 Nov
Do vascular compartments differ in the development of chronic rejection? AT(1) blocker candesartan versus Ace blocker enalapril in an experimental heart transplant model.
2001 Oct
Role of AT1 and AT2 receptor subtypes in salt-sensitive hypertension induced by sensory nerve degeneration.
2001 Oct
ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts.
2001 Oct 12
Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries.
2001 Sep
Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress.
2001 Sep
Patents

Sample Use Guides

Adult Hypertension: 2 DOSAGE AND ADMINISTRATION 2.1 Adult Hypertension The usual recommended starting dose of ATACAND (candesartan cilexetil) is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. ATACAND can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg. Pediatric Hypertension 1 to < 17 Years of Age: Children 1 to < 6 years of age: The dose range is 0.05 to 0.4 mg/kg per day. The recommended starting dose is 0.20 mg/kg (oral suspension). Children 6 to < 17 years of age: For those less than 50 kg, the dose range is 2 to 16 mg per day. The recommended starting dose is 4 to 8 mg. For those greater than 50 kg, the dose range is 4 to 32 mg per day. The recommended starting dose is 8 to 16 mg. Adult Heart Failure: The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.
Route of Administration: Oral
Primary cultures of human retinal endothelial cells (EC) were candesartan treatment (1μg/ml).
Name Type Language
CANDESARTAN
HSDB   INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
Candesartan [WHO-DD]
Common Name English
CV-11974
Code English
CANDESARTAN [VANDF]
Common Name English
CANDESARTAN [USAN]
Common Name English
NSC-759858
Code English
BLOPRESS
Brand Name English
CANDESARTAN [MI]
Common Name English
CANDESARTAN CILEXETIL RELATED COMPOUND G
USP-RS  
Common Name English
candesartan [INN]
Common Name English
CANDEMORE
Brand Name English
CANDESARTAN CILEXETIL RELATED COMPOUND G [USP-RS]
Common Name English
CANDESARTAN [HSDB]
Common Name English
1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID, 2-ETHOXY-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Common Name English
CANDESARTAN CILEXETIL IMPURITY G [EP IMPURITY]
Common Name English
2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLIC ACID
Common Name English
Classification Tree Code System Code
WHO-VATC QC09DB07
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
WHO-VATC QC09CA06
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
WHO-ATC C09CA06
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
NDF-RT N0000000070
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
WHO-ATC C09DA06
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
NCI_THESAURUS C66930
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
NDF-RT N0000175561
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
WHO-ATC C09DX06
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
WHO-VATC QC09DA06
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
WHO-ATC C09DB07
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
LIVERTOX NBK548409
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
Code System Code Type Description
EVMPD
SUB06070MIG
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
MERCK INDEX
m3012
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY Merck Index
INN
7239
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
ChEMBL
CHEMBL1016
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
WIKIPEDIA
CANDESARTAN
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
ChEMBL
CHEMBL1014
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
LACTMED
Candesartan
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
MESH
C081643
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
HSDB
7520
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
PUBCHEM
2541
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
IUPHAR
587
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
NSC
759858
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
DAILYMED
S8Q36MD2XX
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
DRUG BANK
DB00796
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
CHEBI
149509
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
NCI_THESAURUS
C65284
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
RXCUI
214354
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID0022725
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
CHEBI
3347
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
RS_ITEM_NUM
1087870
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
SMS_ID
100000081620
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
USAN
JJ-6
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
FDA UNII
S8Q36MD2XX
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY
CAS
139481-59-7
Created by admin on Fri Dec 15 15:47:59 GMT 2023 , Edited by admin on Fri Dec 15 15:47:59 GMT 2023
PRIMARY